Peter Høngaard Andersen

Chairman of the Board, member of the Board of Directors since June 2019

Education: Holds degrees in Chemistry, Biochemistry and Medicine

Background: Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and Corporate Patents. Founder of Innovation Fund Denmark and Managing Director until May 2019 Chairing Innovative Medicines Initiative (IMI) from 2009 – 2014. Co-founder of e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.

Other ongoing assignments: Board member in Immunovia AB, Monsenso A/S, Venture Partner in Ysios Capital and member of the Scientific Advisory Board in Eir Ventures

Independence: Independent in relation to both the Company and executive management as well as larger shareholders

Scandion Oncology shares and warrants
62,065 shares and 80,377 warrants